Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
NCT04932434 · PDP1 · Joshua Woolley, MD, PhD
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Movement Disorder Society-sponsored Revision of Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Measured over 7 days after first drug dose (which takes place 2-4 weeks after enrollment); 7 and 30 days after second drug dose (which takes place 2 weeks after first drug dose, i.e., 4-6 weeks after enrollment)
Columbia Suicide Severity Rating Scale (C-SSRS)
Measured over 7 days after first drug dose (which takes place 2-4 weeks after enrollment); 7 and 30 days after second drug dose (which takes place 2 weeks after first drug dose, i.e., 4-6 weeks after enrollment)
Enhanced Scale for the Assessment of Positive Symptoms for Parkinson's Disease (eSAPS-PD)
Measured over 7 days after first drug dose (which takes place 2-4 weeks after enrollment); 7 and 30 days after second drug dose (which takes place 2 weeks after first drug dose, i.e., 4-6 weeks after enrollment)
Psychosis and Hallucinations in Parkinson's Disease Questionnaire (PsycH-Q)
Measured over On day of first drug dose (which takes place 2-4 weeks after enrollment); On day of, and 11, 18, and 25 days following second drug dose (which takes place 2 weeks after first drug dose, i.e., 4-6 weeks after enrollment)
Neuropsychiatric Inventory Caregiver Distress Questionnaire (NPI-Q)
Measured over 7 days after first drug dose (which takes place 2-4 weeks after enrollment); 7, 30, and 90 days after second drug dose (which takes place 2 weeks after first drug dose, i.e., 4-6 weeks after enrollment)
11-Dimensional Altered States of Consciousness Rating Scale (11D-ASC)
Measured over Measured on each drug administration session day, following drug dose
Incidence of Adverse Events
Measured over 0-24 hours, 1-7 days, 8-14 days, 15-30 days, and 31-90 days after drug administration
Retention Rate
Measured over 90 days following last drug dose
Treatment Satisfaction Questionnaire (TSQ)
Measured over 30 days following last drug dose
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| University of California, San Francisco | San Francisco | California | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04932434 on ClinicalTrials.gov →
Last updated in the registry 2026-09-03. Registry records change; this page reflects the data build of 2026-10-06.
Related